Roche drug for spinal muscular atrophy hits target in late-stage trial
ZURICH (Reuters) – Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on…
by October Gallery
ZURICH (Reuters) – Roche’s bid to rival Biogen and Novartis in treating spinal muscular atrophy (SMA) got a lift on…
NEW YORK (Reuters) – Eli Lilly and Co’s migraine treatment Emgality on Tuesday became the first drug to gain U.S.…